Emergent BioSolutions Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Emergent BioSolutions reported Q2 2026 revenues of $234.3M (66% YoY growth, beating guidance), but posted a $180.2M net loss due to a $191.3M non-cash impairment charge on NARCAN assets. The naloxone business faces intensifying competition post-OTC approval and generic entry; commercial revenues declined 22% YoY to $52.4M. Management cut full-year 2026 revenue guidance from $720–760M to $645–675M and net loss guidance from $(30)–(10)M to $(245)–(225)M. The company is restructuring, cutting ~90 roles and targeting $40M annualized savings. MCM (medical countermeasures) revenues surged to $168M (188% YoY), driven by $52.7M ACAM2000 and $64.5M BAT contract modifications from the U.S. government.
Why this rating
Major asset write-down signals permanent business value destruction in core commercial product. Revenue guidance cut by ~11% mid-year is material relative to $343M market cap. MCM strength partially offsets but naloxone collapse is trajectory-altering.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.